HDR Brachytherapy in the Management of High-Risk Prostate Cancer.

Item

http://www.wikidata.org/entity/Q35810413

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

HDR Brachytherapy in the Management of High-Risk Prostate Cancer.

@ast

HDR Brachytherapy in the Management of High-Risk Prostate Cancer.

@en

type

Item

label

HDR Brachytherapy in the Management of High-Risk Prostate Cancer.

@ast

HDR Brachytherapy in the Management of High-Risk Prostate Cancer.

@en

prefLabel

HDR Brachytherapy in the Management of High-Risk Prostate Cancer.

@ast

HDR Brachytherapy in the Management of High-Risk Prostate Cancer.

@en

P1476

HDR Brachytherapy in the Management of High-Risk Prostate Cancer.

@en

P2093

Amit Bahl

http://www.w3.org/2001/XMLSchema#string

Raj Persad

http://www.w3.org/2001/XMLSchema#string

Susan Masson

http://www.w3.org/2001/XMLSchema#string

P2860

Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials.

Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.

High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial.

Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: a systematic review.

An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions

High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results.

High dose rate brachytherapy for prostate cancer.

EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

Radial distance of extraprostatic extension measured by ocular micrometer is an independent predictor of prostate-specific antigen recurrence: A new proposal for the substaging of pT3a prostate cancer.

High-dose-rate brachytherapy combined with hypofractionated external beam radiotherapy for men with intermediate or high risk prostate cancer: analysis of short- and medium-term urinary toxicity and biochemical control

P304

980841

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2012/980841

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223990518

http://www.w3.org/2001/XMLSchema#string

P698

22461791

http://www.w3.org/2001/XMLSchema#string

P921

brachytherapy

P932

3296150

http://www.w3.org/2001/XMLSchema#string